Key Points: – Energy Fuels expands capabilities in medical isotope production – Acquisition addresses global shortage of crucial radioisotopes – Potential for repurposing existing process streams for cancer treatments |
Energy Fuels Inc., a leader in uranium and rare earth elements production, has made a strategic move to address the growing demand for medical radioisotopes used in cancer treatments. On August 16, 2024, the company announced its acquisition of RadTran LLC, a private firm specializing in the separation of critical radioisotopes.
This acquisition marks a significant step for Energy Fuels in its plans to develop and produce medical isotopes, particularly radium-226 (Ra-226) and radium-228 (Ra-228). These isotopes are crucial components in the production of actinium-225 (Ac-225) and lead-212 (Pb-212), which are used in emerging targeted alpha therapies (TAT) for cancer treatment.
The global shortage of Ra-226 and Ra-228 has been a major hurdle in the advancement and commercialization of these potentially life-saving therapies. Energy Fuels’ move to acquire RadTran is aimed at addressing this shortage and positioning the company as a leader in this developing industry.
Mark Chalmers, President and CEO of Energy Fuels, emphasized the synergy between the two companies. The acquisition combines Energy Fuels’ processing capabilities at the White Mesa Mill – the only permitted and operating uranium mill in the United States – with RadTran’s intellectual property and expertise in radionuclide separation and concentration.
One of the most innovative aspects of this initiative is Energy Fuels’ potential to recover valuable isotopes from its existing process streams. This approach would essentially recycle material that would otherwise be lost to disposal, repurposing it for use in producing cancer treatments. This not only adds value to Energy Fuels’ operations but also contributes to more sustainable practices in the industry.
The acquisition builds upon a Strategic Alliance Agreement between Energy Fuels and RadTran that has been in place since July 2021. Under this agreement, the companies have been evaluating the feasibility of recovering Ra-226 and Ra-228 from existing uranium process streams at Energy Fuels’ White Mesa Mill in Utah.
Energy Fuels has already made significant progress in this area, receiving regulatory approval and licensing in 2023 for the concentration of R&D quantities of Ra-226 at the Mill. The company is currently completing engineering on its research and development pilot facility for Ra-226 production. In 2024, Energy Fuels plans to set up the first stages of the pilot facility and expects to produce R&D quantities of Ra-226 for testing by end-users.
Looking ahead, Energy Fuels aims to develop capabilities for commercial-scale production of Ra-226 and potentially Ra-228 in 2026-2028. This timeline is contingent on completing engineering design, securing sufficient offtake agreements, and receiving all required regulatory approvals.
The acquisition terms include an initial payment of $1.5 million in cash and $1.5 million in Energy Fuels common shares, along with a 2% royalty on future revenues from radium sales. Additional performance-based milestones could lead to up to $14 million more in cash and shares.
As part of the deal, Saleem Drera PhD, President and CEO of RadTran, will join Energy Fuels as Vice President of Radioisotopes, Radiological Systems, and Intellectual Property. Dr. Drera will lead efforts to integrate RadTran’s proprietary technology and drive innovation in medical radioisotope production.
The urgency of this acquisition is underscored by the extensive clinical research currently underway. Over 30 clinical trials are evaluating Ac-225, with several reaching final pre-approval stages for treating neuroendocrine tumors and leukemia. The current shortfall in Ac-225 production is delaying trials and challenging the transition to full commercial and clinical availability of these promising cancer therapies.
Energy Fuels’ strategic acquisition of RadTran represents a significant step towards addressing critical supply chain issues in the medical radioisotope industry. By leveraging existing facilities and expertise, the company is poised to play a crucial role in supporting the development of innovative cancer treatments, potentially improving outcomes for patients worldwide.